By Sabela Ojea

Phathom Pharmaceuticals said the U.S. Food and Drug Administration approved Voquezna to treat a type of esophagus inflammation.

The commercial-stage biopharmaceutical company said the FDA approved the novel potassium-competitive acid blocker as a new treatment for adults dealing with erosive esophagitis.

The approval is based on positive results from the phase 3 Phalcon-EE study, which enrolled over 1,000 patients in the U.S. and Europe.

Voqezna is expected to be available in the U.S. in December, the company said.

The FDA approval entitles Phathom Pharmaceuticals to receive a $175 million payment, which will fund the commercial launch.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

November 01, 2023 17:35 ET (21:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Phathom Pharmaceuticals (NASDAQ:PHAT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Phathom Pharmaceuticals.
Phathom Pharmaceuticals (NASDAQ:PHAT)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Phathom Pharmaceuticals.